GlassScriptPhysician profile
Anthony J Buscaglia
NPI 1265579536
$4,257.06
in general payments reported to CMS, 2019-2025
29 companies · $920 in 2025
The $920 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $344 · 2021: $328 · 2022: $739 · 2023: $728 · 2024: $870 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,018.00 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $802.01 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $559.89 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Grifols USA, LLC | $218.59 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $212.68 | 2022-2025 | |
| Amgen INC. | $206.76 | 2019-2025 | Tezspire, Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $203.87 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $142.29 | 2020-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $106.19 | 2022-2024 | Yupelri |
| Abbvie INC. | $64.15 | 2022 | |
| Novo Nordisk INC | $63.52 | 2020-2022 | |
| Philips North America LLC | $62.52 | 2019-2024 | (Ak6) Vest Therapy |
| Amarin Pharma, INC. | $55.82 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.17 | 2022-2024 | Glassia |
| Circassia INC. | $52.69 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $52.68 | 2024-2025 | Smartvest |
| Viatris Specialty LLC | $52.04 | 2025 | Yupelri |
| Pfizer INC. | $51.79 | 2023 | |
| Inogen, INC. | $46.18 | 2022-2024 | |
| Vifor Pharma, INC. | $31.99 | 2024 | Zemaira |
| Teva Pharmaceuticals USA, INC. | $31.52 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $31.21 | 2025 | Purified Cortrophin Gel |
| Esperion Therapeutics, INC. | $25.64 | 2020-2021 | |
| Optinose US, INC. | $20.82 | 2024 | |
| Nabriva Therapeutics, Plc | $20.58 | 2021 | |
| Abbott Laboratories | $20.30 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.00 | 2022 | |
| Baxter Healthcare | $16.11 | 2022 | |
| Verona Pharma, INC. | $16.05 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Buscaglia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.